11 December 2008
IBDase: SCIPROM's second FP7 project!IBDase or "Mucosal proteases and their inhibitors in inflammatory bowel disease: From etiopathogenetic insight to innovative therapy" is a Collaborative Project financed by the 7th Framework Programme of the European Union in the HEALTH priority. The IBDase web site is now online at www.ibdase.org.
Inflammatory bowel disease (IBD) is characterised by chronic mucosal inflammation of the gastrointestinal tract and sometimes also other organs. The incidence has been rising in Europe over recent years, and it increasingly also affects children and infants. Nowadays, IBD is diagnosed as often as insulin-dependent diabetes. Although current therapies counteract the inflammatory reaction in the intestinal mucosa and can temporarily induce remission and alleviate symptoms in the patient, there is no cure to the disease.
IBDase addresses the etiology and pathogenesis of IBD with a multidisciplinary plan for innovative diagnosis and therapy focused on mucosal proteases and their inhibitors (P/PIs).
IBDase, a project coordinated by Daniel Lottaz from University of Berne, passed the evaluation threshold with an excellent 14.5 points out of 15 - we are happy to be part of this great project!
Visit our Projects page www.sciprom.ch/projects/projects.html to learn more about IBDase and our other projects ...